Baird Capital portfolio company NeoChord, a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, recently announced successful completion of the first-in-human procedure with the NeoChord NeXuS Transcatheter Mitral Chordal Repair technology (TMVr).

This first-in-human procedure was performed at the University Hospital of Bordeaux in France in collaboration with the Universitätsmedizin Mainz Germany. The NeoChord NeXuS TMVr device is unique from other mitral valve repair technologies in maintaining a natural physiologic functionality of the mitral valve. The patient treated has been discharged from the hospital and is back to a normal lifestyle.

Baird Capital announced its Series C investment in NeoChord in 2015. For the full news release related to this week’s announcement, click here.